Abstract 3274
Background
Little is known regarding the efficacy of ICPi in LCNET.
Methods
Thirty seven consecutive patients (pts) with advanced LCNET were selected from the Davidoff Cancer Center database. These were divided into Groups A1 (pts treated with ICPi, n-23) and A2 (pts not treated with ICPi, n-14). Another cohort of advanced non-small cell lung cancer (NSCLC) pts treated with nivolumab at five Israeli cancer centers in 2015-2016 was chosen as a comparator (Group B, n-270). ORR, PFS with ICPi in Group A1 were assessed (RECIST 1.1), OS with ICPi was compared between Groups A1 and B. OS since advanced disease diagnosis (OSDx) was compared between Groups A1 and A2.
Results
Baseline pts characteristics are presented in the table. In Group A1* (n-21, 2 pts receiving combined ICPi + chemotherapy were excluded), ORR and median PFS with ICPi were 33%, and 4.2 months (95% CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in Groups A1* and B, respectively, 52% of pts in Group A1* and 64% of pts in Group B had died. Median OS with ICPi comprised 11.8 months (95% CI, 3.7-NR) and 6.9 months (95% CI, 5.5-8.1) in Groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95% CI, 10.1-38.9) and 10.3 months (95% CI, 2.6-NR), in Groups A1 and A2, respectively (p-0.54). Abbreviations: Tx- treatment, N – nivolumab, P-pembrolizumab, A- atezolizumab.Table: 1403P Baseline patients characteristics
Group A1* (n-21) | Group B (n-270) | p value | |
---|---|---|---|
Age (median, range), y | 62 (45-77) | 67 (40-99) | 0.004 |
Gender, % | 0.09 | ||
F | 52 | 33 | |
M | 48 | 67 | |
Smoking, % | 1 | ||
Smokers | 86 | 77 | |
Never smokers | 14 | 14 | |
NA | 9 | ||
ECOG PS at ICPi, % | 0.06 | ||
0/1 | 67 | 46 | |
2-4 | 24 | 47 | |
NA | 9 | 7 | |
Previous Tx lines, % | 0.2 | ||
0 | 10 | 6 | |
1 | 80 | 66 | |
2-4 | 10 | 25 | |
NA | 10 (3) | ||
ICPi type: N/P/A/other, % | 62/9/20/9 | 100/0/0/0 | NA |
Conclusions
In advanced LCNET, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future prospective research is needed to clarify the impact of ICPi on OS in LCNET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Zer: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca, Roche, BMS, MSD, BI, TAKADA. E. Dudnik: Research grant / Funding (self): Roche, Boehringer Ingelheim; Advisory / Consultancy: Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD, BMS, Novartis, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract